Quanterix Corporation, a US-based biomarker analysis technology provider backed by diagnostics technology producers BioMerieux and Stratec Biomedical, has raised $8.5m in a private placement.
The placement was led by funds and accounts advised by investment firm T. Rowe Price Associates and will be added to the $46m in series D funding Quanterix secured in March 2016. Quanterix has now raised $102m altogether.
Founded in 2007, Quanterix has developed a digital health product called Simoa that digitises the biomarker analysis process, helping diseases to be detected more quickly. It will use the funding to expand its portfolio of assays and create new instruments.
The 2016 funding came from Arch Overage Fund, Cormorant Asset Management, Trinitas Capital, Arch Venture Partners, Bain Capital Ventures, Hercules Capital, Tufts University and private investor David Walt.
Stratec took a 7% stake in the company in 2011 as part of a joint development agreement, while BioMerieux invested $15m in a $18.5m series C round in 2012 that included Arch Venture Partners, Bain Capital Ventures, Flagship Ventures and In-Q-Tel.